Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
530.7
％Wording
Conditional
How definitive the wording is.Results for this period
Third quarter令和７年６月１日〜令和８年２月28日ConsolidatedJapanese GAAPNet Sales50,556Millions of yenYear on year +8.5%Progress 75.7%
Operating profit603Millions of yenYear on year +530.7%Progress 53.7%
Ordinary income419Millions of yenProgress 44.5%
Net income attributable to owners of the parent-13Millions of yen
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share(¥1.20)
Financial position at period-end
Total assets31,428Millions of yen
of which net assets 6,705 Millions of yenEquity ratio 20.6%vs. prior year-end -0.3pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueDispensing Pharmacy Business 43,004 Millions of yen (YoY +12.3%), Retail Business 6,009 Millions of yen (YoY -9.3%), Medical Records Storage and Management Business 489 Millions of yen (YoY +6.6%), Medical mall management business 383 Millions of yen (YoY -0.3%), Other 669 Millions of yen (YoY -16.7%)
Segment profitDispensing Pharmacy Business 974 Millions of yen (YoY +222.2%), Retail Business -68 Millions of yen, Medical Records Storage and Management Business 77 Millions of yen (YoY +102.6%), Medical mall management business 68 Millions of yen (YoY -15.1%), Other -129 Millions of yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales66,795 Millions of yen (YoY +5.2%)
Operating profit1,123 Millions of yen (YoY +282.2%)
Ordinary income941 Millions of yen (YoY +587.3%)
Net income266 Millions of yen
Revision to Earnings ForecastNo
Annual Dividend Forecast¥14 → ¥14（0.0%）
Factors Behind Changes in Business Performance
調剤薬局事業では、M&Aによる店舗数増加、新規出店による応需処方せん枚数増加、グループ入りした店舗の利益増加、調剤技術料の増加、運営効率化による販管費率減少が寄与した。物販事業では不採算店舗閉店、競合出店、季節性医薬品の販売不調が影響した。医学資料保管・管理事業では保管料売上、一時的な保管資料廃棄売上、労務費等の削減が寄与した。医療モール経営事業では人件費増加と設備投資による減価償却費増加が減益要因となった。その他事業では案件成約数・訪問回数の減少、新製品開発に伴う償却費が影響した。
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidation表紙では重要な変更なし、新規0社・除外0社。一方、セグメント注記には、非連結子会社であったｎｅｘｔ ＰＨ株式会社を新たに連結の範囲に含めたとの記載あり。
Impairment loss22 Millions of yen
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets 18 Millions of yen, Subsidy Income 46 Millions of yen, Reversal of allowance for doubtful accounts 27 Millions of yen / Extraordinary loss Loss on sale of fixed assets 0 Millions of yen, Loss on Disposal of Fixed Assets 7 Millions of yen, Loss on reduction of fixed assets 45 Millions of yen, Impairment Losses 22 Millions of yen, Loss on cancellation of lease agreements 1 Millions of yen
Depreciation and amortization570 Millions of yen
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingWhether applicable Yes / Subject person Analysts and institutional investors
Issued Shares at Period-End12,060,381 Shares
Treasury Shares at Period-End557,856 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 令和７年６月１日〜令和８年２月28日 |
| Net Sales | 50,556 Millions of yen (YoY +8.5%) |
| Operating profit | 603 Millions of yen (YoY +530.7%) |
| Ordinary income | 419 Millions of yen |
| Profit attributable to owners of the parent | -13 Millions of yen |
| Net income per share | (¥1.20) |
| Equity ratio | End of the current fiscal period 20.6 / End of previous period 20.9 |
| Total assets | 31,428 Millions of yen |
| Net assets | 6,705 Millions of yen |
| Full-year earnings forecast | Net Sales 66,795 Millions of yen (YoY +5.2%) / Operating profit 1,123 Millions of yen (YoY +282.2%) / Ordinary income 941 Millions of yen (YoY +587.3%) / Net income 266 Millions of yen |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥14 → ¥14（0.0%） |
| Segment revenue | Dispensing Pharmacy Business 43,004 Millions of yen (YoY +12.3%), Retail Business 6,009 Millions of yen (YoY -9.3%), Medical Records Storage and Management Business 489 Millions of yen (YoY +6.6%), Medical mall management business 383 Millions of yen (YoY -0.3%), Other 669 Millions of yen (YoY -16.7%) |
| Segment profit | Dispensing Pharmacy Business 974 Millions of yen (YoY +222.2%), Retail Business -68 Millions of yen, Medical Records Storage and Management Business 77 Millions of yen (YoY +102.6%), Medical mall management business 68 Millions of yen (YoY -15.1%), Other -129 Millions of yen |
| Depreciation and amortization | 570 Millions of yen |
| Impairment loss | 22 Millions of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 18 Millions of yen, Subsidy Income 46 Millions of yen, Reversal of allowance for doubtful accounts 27 Millions of yen / Extraordinary loss Loss on sale of fixed assets 0 Millions of yen, Loss on Disposal of Fixed Assets 7 Millions of yen, Loss on reduction of fixed assets 45 Millions of yen, Impairment Losses 22 Millions of yen, Loss on cancellation of lease agreements 1 Millions of yen |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | 表紙では重要な変更なし、新規0社・除外0社。一方、セグメント注記には、非連結子会社であったｎｅｘｔ ＰＨ株式会社を新たに連結の範囲に含めたとの記載あり。 |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Analysts and institutional investors |
| Issued Shares at Period-End | 12,060,381 Shares |
| Treasury Shares at Period-End | 557,856 Shares |
| Factors Behind Changes in Business Performance | 調剤薬局事業では、M&Aによる店舗数増加、新規出店による応需処方せん枚数増加、グループ入りした店舗の利益増加、調剤技術料の増加、運営効率化による販管費率減少が寄与した。物販事業では不採算店舗閉店、競合出店、季節性医薬品の販売不調が影響した。医学資料保管・管理事業では保管料売上、一時的な保管資料廃棄売上、労務費等の削減が寄与した。医療モール経営事業では人件費増加と設備投資による減価償却費増加が減益要因となった。その他事業では案件成約数・訪問回数の減少、新製品開発に伴う償却費が影響した。 |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.売上高は、前連結会計年度のM&Aによる店舗数拡大に伴う調剤売上高の増加により増収となった。営業利益・経常利益は、調剤薬局事業の利益改善、M&Aでグループ入りした店舗の利益増加、本部業務効率化による販管費率の減少により増益となった。一方、M&A費用の発生と一部子会社で損失が継続したため、親会社株主に帰属する四半期純利益は損失となった。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.